

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

HOUGHTON ET AL.

APPLICATION NO: 10/530,618

FILED: FEBRUARY 23, 2006

FOR: USE OF IMATINIB (GLIVEC, STI-571) TO INHIBIT BREAST  
CANCER RESISTANCE PROTEIN (BCRP)-MEDIATED  
RESISTANCE TO THERAPEUTIC AGENTS

**MS: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This reply is in response to the Office Action of September 14, 2007, to which a reply was due October 14, 2007. A petition for a three-month extension of time is included with this reply, thus extending the time to respond to January 14, 2008. Please amend the above-identified application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 3 of this paper.